Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 154

Results For "India"

3744 News Found

Rusan Pharma achieves GMP approvals from TGA (Australia) and ANVISA (Brazil) for its manufacturing facility in Kandla SEZ
Drug Approval | December 17, 2024

Rusan Pharma achieves GMP approvals from TGA (Australia) and ANVISA (Brazil) for its manufacturing facility in Kandla SEZ

The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market


Kiran Mazumdar-Shaw honored by ISQ with ‘Jamsetji Tata Award’ for pioneering biosciences movement
News | December 16, 2024

Kiran Mazumdar-Shaw honored by ISQ with ‘Jamsetji Tata Award’ for pioneering biosciences movement

Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International


Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care
News | December 16, 2024

Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care

Harnessing advanced data analysis for early detection, prevention and better outcomes


Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio
News | December 14, 2024

Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio

The trademark rights for these brands will be transferred to Lupin by March next year.


Biocon Biologics recognized as Asia IP Elite for 2024 by IAM
News | December 12, 2024

Biocon Biologics recognized as Asia IP Elite for 2024 by IAM

Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list


Metropolis Healthcare acquires Core Diagnostics for Rs. 246.8 Cr
Clinical Trials | December 09, 2024

Metropolis Healthcare acquires Core Diagnostics for Rs. 246.8 Cr

Aims to become India’s leading cancer testing company


Lupin receives tentative approval from USFDA for Abacavir, Dolutegravir and Lamivudine tablets for oral suspension
Drug Approval | December 09, 2024

Lupin receives tentative approval from USFDA for Abacavir, Dolutegravir and Lamivudine tablets for oral suspension

The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen


Laurus Labs invests in Laurus Bio
News | December 09, 2024

Laurus Labs invests in Laurus Bio


Lupin’s R&D facility in Pune bags LEED Platinum Certification
News | December 06, 2024

Lupin’s R&D facility in Pune bags LEED Platinum Certification

Reaffirms Lupin’s commitment to sustainable resource management